Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | PLG | P00747 | 3/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 4/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650962 | 0.94 | L3MBTL1 (0.58) | L3MBTL1PLGCTSSCTSBCTSK | |
| SCHEMBL4651314 | 0.87 | TACR2 (0.54) | L3MBTL1PLGKLKB1PTPN1PTPN22 | |
| SCHEMBL6571419 | 0.86 | PTPN1 (0.53) | PLGPTPN1PTPN22PRSS1PRSS2 | |
| SCHEMBL6571423 | 0.86 | PTPN1 (0.53) | PLGPTPN1PTPN22PRSS1PRSS2 | |
| SCHEMBL4315647 | 0.85 | KLKB1 (0.56) | PLGKLKB1PTPN1PTPN22FOLH1 | |
| SCHEMBL4315645 | 0.85 | KLKB1 (0.56) | PLGKLKB1PTPN1PTPN22FOLH1 | |
| SCHEMBL6571743 | 0.85 | KLKB1 (0.56) | PLGKLKB1PTPN1PTPN22FOLH1 | |
| SCHEMBL4650362 | 0.85 | GRIA1 (0.55) | L3MBTL1CTSSCTSKCTSLGRIA1 | |
| SCHEMBL6575436 | 0.84 | PTPN1 (0.51) | PLGKLKB1PTPN1PTPN22PRSS1 | |
| SCHEMBL4650952 | 0.83 | MMP2 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301474-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | Array Biopharma Inc. (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002004412-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2002-01-17 | — | — | WO | claimed |
| EP-1301474-B1 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | disclosed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040003-A1 | Preparation of phosphatase inhibitors | PTPRS, PTPRO, PTPRR | L3MBTL1 3722/4885PLG 3656/4885CTSS 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.